Speech latency may predict schizophrenia trial response, boosting drug-placebo separation

Researchers have identified a promising new speech biomarker that could significantly enrich clinical trials by reducing sample size requirements and enhancing statistical outcomes. By using speech latency, participants who are likely to show a high placebo response can be identified and excluded.

…